Spots Global Cancer Trial Database for Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses
Official Title: A Multi-center, Randomized, Double-blind, Parallel-group, Vehicle-controlled Study to Determine the Safety of PEP005 0.0025%, 0.01% and 0.05% Gel With Two Treatment Schedules, Day 1 & 2 or Day 1 & 8 Applications to Actinic Keratoses
Study ID: NCT00107965
Conditions
Study Description
Brief Summary: The purpose of this study is to determine whether topical application of PEP005 is safe for the treatment of actinic keratoses.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
Siller Medical, Brisbane, Queensland, Australia
Skin and Cancer Foundation, Melbourne, Victoria, Australia
Monash Medical Centre, Melbourne, Victoria, Australia
Fremantle Dermatology, Fremantle, Western Australia, Australia
Private Dermaology Clinic, Fremantle, Western Australia, Australia
Contact Details
Name: Greg Siller
Affiliation:
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
